In Depth 13 Jun 2023 Abeta-targeting antibodies pave the way for Alzheimer’s disease vaccines …treatment of Alzheimer’s disease In September 2022, the monoclonal antibody lecanemab, which targets a toxic species of Abeta protein, slowed cognitive decline in early Alzheimer’s disease by approximately 30% in… June 13, 2023 - 7 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 7 Jan 2020 Update: Chinese Pharma Enlists Synaffix’s ADC Technology for Second Drug …treatment based on antibody-drug conjugate technology from the Dutch company Synaffix. Synaffix develops technology to produce antibody-drug conjugates, commonly known as ADCs, which are antibodies with toxic chemotherapy drugs attached…. January 7, 2020 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Interview 25 Oct 2018 Mastering the Competitive World of Immuno-oncology …of the antibody field and started his first company, 4-Antibody, in 2004. Before a successful sale to Agenus in 2014, the company developed therapeutic antibodies for a range of different… October 25, 2018 - 5 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 15 Dec 2022 Solve Therapeutics launches to tackle cancer …reviewing other potential in-licensing opportunities as well as performing in-house antibody discovery research. The company’s focus is on the development of novel mAbs, antibody drug conjugates incorporating next-generation linker and… December 15, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
More News! 25 Mar 2019 Swedish Biotech’s Stock Severely Hit by Failure of Biogen’s Alzheimer’s Drug …were scheduled to start a phase III trial of an antibody treatment for Alzheimer’s. Although the antibody is not the same as Biogen’s, both antibodies target pathological forms of a… March 25, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Best in Biotech 15 Mar 2023 10 immunotherapy companies making waves in 2023 …solid tumors. The drug is a monoclonal antibody, which is a type of protein that can bind to antigens of cancer cells; flagging the cells and could trigger the destruction… March 15, 2023 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 2 Apr 2025 Beyond amyloid: The search for the next big thing in Alzheimer’s treatment …the amyloid-plaques-targeting antibody showed some plaque clearance, the cognitive data were mixed at best. Then came Leqembi in 2023. This second-generation amyloid-targeting antibody showed a modest but statistically significant slowing… April 2, 2025 - 10 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 1 Jul 2022 License submitted to FDA for drug to help those with large B-cell lymphoma A biologics license application has been submitted to the US Food and Drug Administration (FDA) for an antibody to treat patients with B-cell lymphoma. Genmab A/S is a biotechnology company… July 1, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
Best in Biotech 5 Aug 2025 10 oncology deals in 2025 spotlight where industry leaders are betting big …payments through 2028, and up to $7.6 billion in milestone payments. The partnership involves the co-development and co-commercialization of BioNTech’s investigational bispecific antibody BNT327 across numerous solid tumor types, as… August 5, 2025 - 10 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 22 Aug 2025 The Sanofi pipeline in 2025: Is the play-to-win strategy working? …Sanofi acquires the full Vigil pre-clinical neurodegenerative pipeline. However, the TREM2 agonist antibody iluzanebart (VGL101), which Vigil had been developing for rare microgliopathies, was excluded from the acquisition, and rights… August 22, 2025 - 12 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Interview 30 Oct 2017 Meet the Covagen Co-Founder that Closed Europe’s Biggest Acquisition in 2014 …So what was the technology that Covagen developed that J&J took such an interest in? We started with the development of antibody alternatives, with Fynomers — small proteins of about… October 30, 2017 - 9 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 28 Feb 2017 New Antibodies to Target the Respiratory Syncytial Virus …targeting respiratory syncytial virus (RSV) that were discovered by Adimab. On top of that, the Gates Foundation will support Arsanis with €8.8M ($9.3M) to advance the selected antibody to IND… February 28, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email